MA38661A1 - Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine - Google Patents

Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine

Info

Publication number
MA38661A1
MA38661A1 MA38661A MA38661A MA38661A1 MA 38661 A1 MA38661 A1 MA 38661A1 MA 38661 A MA38661 A MA 38661A MA 38661 A MA38661 A MA 38661A MA 38661 A1 MA38661 A1 MA 38661A1
Authority
MA
Morocco
Prior art keywords
heteroaromatic compounds
preparation
compounds
cognitive impairment
schizophrenia
Prior art date
Application number
MA38661A
Other languages
English (en)
Inventor
Lei Zhang
Michael Eric Green
Amy Beth Dounay
Michael Aaron Brodney
Jennifer Elizabeth Davoren
Ivan Viktorovich Efremov
David Lawrence Firman Gray
Jaclyn Louise Henderson
Chewah Lee
Scot Richard Mente
Steven Victor O'neil
Bruce Nelsen Rogers
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51205521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38661(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA38661A1 publication Critical patent/MA38661A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne, en partie, des composés représentés par la formule (i) : (i) et leurs sels pharmaceutiquement acceptables ; des procédés pour leur préparation ; des intermédiaires utilisés dans leur préparation ; et des compositions contenant de tels composés ou sels et leurs utilisations pour le traitement de pathologies médiées par le d1 (ou associées au d1), notamment la schizophrénie (par ex., ses symptômes cognitifs et négatifs), le déficit cognitif (par ex., le déficit cognitif associé à la schizophrénie, la ma, la mp ou une pharmacothérapie), le déclin des facultés mentales lié à l'âge, la démence et la maladie de parkinson.
MA38661A 2013-06-27 2014-06-13 Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine MA38661A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840144P 2013-06-27 2013-06-27
PCT/IB2014/062217 WO2014207601A1 (fr) 2013-06-27 2014-06-13 Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine

Publications (1)

Publication Number Publication Date
MA38661A1 true MA38661A1 (fr) 2017-03-31

Family

ID=51205521

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38661A MA38661A1 (fr) 2013-06-27 2014-06-13 Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine

Country Status (42)

Country Link
US (11) US9527831B2 (fr)
EP (2) EP3421462B1 (fr)
JP (1) JP6026024B2 (fr)
KR (1) KR101781723B1 (fr)
CN (1) CN105324376B (fr)
AP (1) AP2015008844A0 (fr)
AR (1) AR096748A1 (fr)
AU (1) AU2014300673B2 (fr)
BR (1) BR122023004130B1 (fr)
CA (1) CA2916653C (fr)
CL (1) CL2015003735A1 (fr)
CR (1) CR20150634A (fr)
CU (1) CU24334B1 (fr)
DK (2) DK3013813T3 (fr)
DO (1) DOP2015000302A (fr)
EA (1) EA028637B1 (fr)
EC (1) ECSP16003103A (fr)
ES (2) ES2729630T3 (fr)
FI (1) FI3421462T3 (fr)
GE (1) GEP20186811B (fr)
GT (1) GT201500350A (fr)
HR (2) HRP20191163T1 (fr)
HU (2) HUE043705T2 (fr)
IL (1) IL242480B (fr)
MA (1) MA38661A1 (fr)
MD (1) MD20150122A2 (fr)
MX (2) MX382599B (fr)
NI (1) NI201500179A (fr)
NZ (1) NZ713762A (fr)
PE (1) PE20160664A1 (fr)
PH (1) PH12015502502A1 (fr)
PL (2) PL3013813T3 (fr)
PT (2) PT3013813T (fr)
RS (2) RS64342B1 (fr)
SG (1) SG11201509186TA (fr)
TN (1) TN2015000547A1 (fr)
TR (1) TR201907981T4 (fr)
TW (1) TWI508957B (fr)
UA (1) UA112945C2 (fr)
UY (1) UY35628A (fr)
WO (1) WO2014207601A1 (fr)
ZA (1) ZA201508252B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015005812A (es) 2012-11-08 2015-09-23 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
CN105324376B (zh) 2013-06-27 2017-06-23 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
CR20160494A (es) * 2014-04-25 2016-12-20 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
WO2015162518A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
WO2015162515A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
WO2015166370A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
US9745317B2 (en) 2014-04-28 2017-08-29 Pfizer Inc. Heterocyclic compounds and their use as dopamine D1 ligands
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
LT3389727T (lt) 2015-12-18 2020-10-12 Janssen Pharmaceutica Nv Radioaktyviai pažymėti mglur2/3 pet ligandai
JP6929285B2 (ja) 2015-12-18 2021-09-01 ヤンセン ファーマシューティカ エヌ．ベー． 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド
RU2712455C1 (ru) * 2016-01-15 2020-01-29 Пфайзер Инк. 6,7,8,9-тетрагидро-5h-пиридо[2,3-d]азепиновые лиганды дофаминовых рецепторов d3
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
PE20190408A1 (es) 2016-03-30 2019-03-14 Ishihara Sangyo Kaisha Compuesto de piridazinona o su sal y herbicida que lo contiene
WO2018157842A1 (fr) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 Utilisation d'un inhibiteur fto d'acide benzoïque 2-(phénylamino substitué) dans le traitement de la leucémie
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
TW202206422A (zh) * 2020-04-23 2022-02-16 美商普雷辛肯公司 用於ｃｄ７３調節之化合物及方法及其適應症
PY2167565A (es) * 2020-08-14 2022-08-08 Syngenta Crop Protection Ag Proceso químico
AU2022402852A1 (en) 2021-12-03 2024-06-20 Abbvie Inc. Solid state forms of tavapadon and processes for preparation thereof
US20250145588A1 (en) * 2022-01-29 2025-05-08 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of tavapadon, and preparation method therefor and use thereof
KR20260052086A (ko) * 2023-08-11 2026-04-17 맨카인드 파마 리미티드 Gpr119 작용제의 약제학적 제형 및 이들의 용도
WO2025144911A1 (fr) 2023-12-27 2025-07-03 Pfizer Inc. Formes solides de 6-[4-[[3-(difluorométhoxy)-2-pyridinyl]oxy]-2-méthylphényl]-1,5-diméthyl-2,4(1h, 3h)-pyrimidinedione, a
WO2026076441A1 (fr) * 2024-10-04 2026-04-09 Cerevel Therapeutics, Llc Formes posologiques orales solides comprenant du tavapadon

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5025142B1 (fr) 1969-07-30 1975-08-21
JPS5039272B1 (fr) 1970-07-14 1975-12-16
JPS5025142A (fr) 1973-07-06 1975-03-17
JPS5039272A (fr) 1973-08-10 1975-04-11
JPS5516432B2 (fr) 1974-05-28 1980-05-01
JPS51113899A (en) 1975-03-27 1976-10-07 Yoshitomi Pharmaceut Ind Ltd Method for preparing novel tetrazole derivatives
JPS522031A (en) 1975-06-24 1977-01-08 Japan Niyuupureito Hokushiyou Sunshade device
EP0002812B1 (fr) 1978-01-02 1982-02-03 Ciba-Geigy Ag Phénoxyalcoyloxazolines, leur préparation, compositions les contenant et leur application comme herbicides
EP0101662A3 (fr) 1982-06-25 1985-12-04 Ciba-Geigy Ag Acides benzoylparabanoiques
US4550108A (en) 1983-08-17 1985-10-29 Ciba Geigy Corporation 1,3,5-Oxadiazine-2,4-diones and pesticidal use
US4723015A (en) 1983-10-17 1988-02-02 Ciba-Geigy Corporation Certain insecticidal N-2-pyridyloxyphenylbenzimidates
IL73611A0 (en) 1983-12-06 1985-02-28 Nippon Soda Co 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides
JPS61275271A (ja) 1985-05-30 1986-12-05 Nippon Soda Co Ltd １，２，４−オキサ（チア）ジアゾリン誘導体、その製造方法，殺虫剤及び農園芸用殺菌剤
DE3545569A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3545786A1 (de) 1985-12-21 1987-06-25 Schering Ag Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung
DE3631511A1 (de) 1986-09-12 1988-03-24 Schering Ag 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel
EP0296518A1 (fr) 1987-06-22 1988-12-28 Ciba-Geigy Ag Dérivés de phényléthers comme microbicide, procédé de leur préparation et leur application
DE3826855A1 (de) * 1988-08-06 1990-02-15 Cassella Ag 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
JPH0259573A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ２（１ｈ）−ピリミジノン誘導体又はその塩類
JPH0259574A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ピラジノン誘導体又はその塩類
US5066667A (en) 1989-06-26 1991-11-19 Ciba-Geigy Corporation Thioxotetrazolines and insecticidal use thereof
ATE111901T1 (de) 1990-01-18 1994-10-15 Nissan Chemical Ind Ltd Uracilderivate und pestizide, die diese als wirksame stoffe enthalten.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03261783A (ja) 1990-03-12 1991-11-21 Suntory Ltd １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
JP3018422B2 (ja) 1990-07-27 2000-03-13 日東紡績株式会社 床 材
US5630962A (en) 1990-12-19 1997-05-20 Hoechst Aktiengesellschaft 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH05202031A (ja) 1992-01-28 1993-08-10 Nissan Chem Ind Ltd Ｎ−アミノピリミジンジオン誘導体および除草剤
EP0630370A1 (fr) 1992-03-11 1994-12-28 E.I. Du Pont De Nemours And Company Oxazolidinones fongicides
US5482951A (en) 1992-05-29 1996-01-09 Kumiai Chemical Industry Co., Ltd. Triazole derivatives as well as insecticide and acaricide
AU4950793A (en) 1992-08-31 1994-03-29 Ciba-Geigy Ag 4,5-dicyanoimidazole derivatives and pesticidal compositions containing them
KR0151364B1 (ko) 1992-12-25 1998-10-15 시모무라 도오루 헤테로 고리 유도체 및 유해 생물 방제제
JP3682075B2 (ja) 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
EP0712847A4 (fr) 1993-08-11 1997-05-28 Nippon Soda Co Derive d'imidazole et son procede de production, et substance anti-nuisibles
JPH0873446A (ja) 1994-04-22 1996-03-19 Nippon Soda Co Ltd ヘテロ環化合物および殺虫・殺ダニ剤
JPH0827120A (ja) 1994-07-08 1996-01-30 Nissan Chem Ind Ltd テトラヒドロピリミジノン誘導体
JPH08217777A (ja) 1995-02-10 1996-08-27 Nippon Nohyaku Co Ltd ２−ピラゾリン−５−オン誘導体及びその中間体並びに除草剤
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH09291282A (ja) 1996-04-26 1997-11-11 Sumitomo Chem Co Ltd 安定化した液晶材料およびこれを用いた液晶素子
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999021837A1 (fr) * 1997-10-27 1999-05-06 Isk Americas Incorporated Composes benzeniques substitues, technique de production et compositions herbicides et defoliantes contenant ces composes
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
US6413992B1 (en) 1998-10-23 2002-07-02 Dow Agrosciences Llc 3-(substituted pyridyl)-1,2,4-triazole compounds
GB9903671D0 (en) 1999-02-17 1999-04-14 Cenes Ltd Dopamine D-1 receptor agonist compounds
MXPA02007047A (es) 2000-01-18 2002-12-13 Pfizer Prod Inc Antagonista del factor liberador de corticotropina.
AU2001244614A1 (en) 2000-04-04 2001-10-15 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
WO2002000647A1 (fr) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa a substitution heteroaryl-phenyle
US6476055B1 (en) 2001-03-28 2002-11-05 Nippon Soda Co. Ltd. 5,5-disubstituted thiazolidine derivative pesticides
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
WO2002090335A1 (fr) 2001-05-09 2002-11-14 Sumitomo Chemical Takeda Agro Company, Limited Composes de type azole, methode de preparation et utilisation desdits composes
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2004018410A1 (fr) 2002-08-26 2004-03-04 Nissan Chemical Industries, Ltd. Compose benzalinide substitue et agent antiparasitaire
CA2505361A1 (fr) 2002-11-11 2004-05-27 Bayer Healthcare Ag Derives de phenyl- ou heteroarylamino-alcanes comme antagonistes du recepteur ip
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
EP1628666B1 (fr) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Composes et leurs utilisations pour la modulation de l'amyloide-beta
US6969744B2 (en) 2003-06-19 2005-11-29 University Of Southern Mississippi Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation
RS20060143A (sr) 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
WO2005051932A1 (fr) 2003-11-28 2005-06-09 Nippon Soda Co., Ltd. Derive arylheterocycle, bactericide et insecticide agricoles ou horticoles
JP2005272452A (ja) 2004-02-23 2005-10-06 Nissan Chem Ind Ltd 置換ベンズアニリド化合物及び有害生物防除剤
CN1946391A (zh) 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
TW200612827A (en) 2004-08-25 2006-05-01 Sumitomo Chemical Co Insecticide composition
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
WO2007105637A1 (fr) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
CA2647338A1 (fr) 2006-04-28 2007-11-08 Avexa Limited Inhibiteurs de l'integrase-3
EP2256496A3 (fr) 2006-09-21 2011-03-16 Piramal Life Sciences Limited Procédé d'identification de composants qui agissent en tant que sensibilisateurs à l'insuline
BRPI0718510A2 (pt) 2006-09-21 2013-11-19 Piramal Life Sciences Ltd Derivados de 3-amino piridina para o tratamento de desordens metabólicas
US7981893B2 (en) 2006-10-19 2011-07-19 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
EP1916240A1 (fr) 2006-10-25 2008-04-30 Syngeta Participations AG Nouveaux derivés de pyridazine
DE102007003036A1 (de) 2006-12-20 2008-06-26 Bayer Cropscience Ag Pyrimidinylpyrazole
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
US8513286B2 (en) 2007-02-22 2013-08-20 Syngenta Crop Protection Llc Iminipyridine derivatives and their uses as microbiocides
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101294257B (zh) 2007-04-23 2014-06-18 株式会社神户制钢所 焊接热影响部的韧性优异的钢材及其制造方法
JP2009062290A (ja) 2007-09-04 2009-03-26 Takeda Chem Ind Ltd シクロプロパン化合物
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
BRPI0812978A2 (pt) 2007-10-31 2014-12-16 Abbott Gmbh & Co Kg Compostos de benzenosulfonamida adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
WO2009142732A2 (fr) 2008-05-20 2009-11-26 Cephalon, Inc. Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h<sb>3</sb>)
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
CA2736970A1 (fr) * 2008-09-12 2010-03-18 Biolipox Ab Derives de pyrimidinone pour utilisation en tant que medicaments
CN102307863B (zh) 2008-12-03 2014-05-07 日本农药株式会社 嘧啶衍生物、含该衍生物的园艺用杀虫剂及其使用方法
WO2010068788A1 (fr) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides hétérocycliques en tant qu'inhibiteurs de la btk
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
EP2246335A1 (fr) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyridineamides en tant que pesticides
MX336711B (es) * 2010-03-04 2016-01-28 Merck Sharp & Dohme Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
KR20130069640A (ko) 2010-04-23 2013-06-26 키네타, 인크. 항-바이러스 화합물
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
SI2603513T1 (sl) 2010-08-10 2020-07-31 Takeda Pharmaceutical Company Limited Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator receptorja AMPA
EP2616441B1 (fr) 2010-09-17 2019-08-07 Purdue Pharma L.P. Composés de pyridine et ses utilisations
AU2012300567B2 (en) * 2011-09-02 2016-03-10 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
MX2015005812A (es) 2012-11-08 2015-09-23 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
EP2917216B1 (fr) * 2012-11-08 2017-10-18 Pfizer Inc Composés hétéroaromatiques utilisés comme ligands de la dopamine d1
WO2014119770A1 (fr) * 2013-01-30 2014-08-07 住友化学株式会社 Composé pyridazinone et herbicide comprenant celui-ci
CN105324376B (zh) * 2013-06-27 2017-06-23 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途

Also Published As

Publication number Publication date
TW201512185A (zh) 2015-04-01
KR101781723B1 (ko) 2017-10-23
FI3421462T3 (fi) 2023-06-26
US10696658B2 (en) 2020-06-30
CN105324376A (zh) 2016-02-10
US20210300899A1 (en) 2021-09-30
JP2016531083A (ja) 2016-10-06
PL3013813T3 (pl) 2019-10-31
GT201500350A (es) 2017-09-28
CN105324376B (zh) 2017-06-23
DK3013813T3 (da) 2019-06-03
AP2015008844A0 (en) 2015-11-30
PE20160664A1 (es) 2016-07-09
UY35628A (es) 2015-01-30
CA2916653A1 (fr) 2014-12-31
AU2014300673B2 (en) 2017-12-14
US9822097B2 (en) 2017-11-21
TWI508957B (zh) 2015-11-21
PT3013813T (pt) 2019-06-14
MX2015017169A (es) 2016-04-06
EA201592146A1 (ru) 2016-05-31
DK3421462T3 (da) 2023-06-12
MD20150122A2 (ro) 2016-05-31
US20150005313A1 (en) 2015-01-01
US9527831B2 (en) 2016-12-27
US20240317713A1 (en) 2024-09-26
CA2916653C (fr) 2017-07-18
HK1215435A1 (zh) 2016-08-26
SG11201509186TA (en) 2016-01-28
US20150196561A1 (en) 2015-07-16
US11964961B2 (en) 2024-04-23
US10421744B2 (en) 2019-09-24
US20180037571A1 (en) 2018-02-08
US9107923B2 (en) 2015-08-18
PT3421462T (pt) 2023-06-29
NI201500179A (es) 2016-02-11
CU24334B1 (es) 2018-04-03
US9139561B2 (en) 2015-09-22
EP3013813A1 (fr) 2016-05-04
PH12015502502A1 (en) 2016-02-22
US20260125364A1 (en) 2026-05-07
RS59018B1 (sr) 2019-08-30
AU2014300673A1 (en) 2015-11-12
BR122023004130B1 (pt) 2023-12-12
EP3013813B1 (fr) 2019-04-03
CR20150634A (es) 2016-01-04
TR201907981T4 (tr) 2019-06-21
IL242480B (en) 2019-09-26
RS64342B1 (sr) 2023-08-31
NZ713762A (en) 2018-03-23
HRP20191163T1 (hr) 2019-10-04
ES2729630T3 (es) 2019-11-05
MX382599B (es) 2025-03-13
KR20160014665A (ko) 2016-02-11
CL2015003735A1 (es) 2016-06-24
IL242480A0 (en) 2016-02-01
ECSP16003103A (es) 2017-08-31
HRP20230546T1 (hr) 2023-08-04
HUE043705T2 (hu) 2019-09-30
JP6026024B2 (ja) 2016-11-16
CU20150180A7 (es) 2016-05-30
PL3421462T3 (pl) 2023-09-11
AR096748A1 (es) 2016-02-03
DOP2015000302A (es) 2016-02-29
HUE062265T2 (hu) 2023-10-28
EP3421462B1 (fr) 2023-04-05
EA028637B1 (ru) 2017-12-29
ZA201508252B (en) 2019-04-24
US20190367485A1 (en) 2019-12-05
UA112945C2 (uk) 2016-11-10
US20200283407A1 (en) 2020-09-10
US20150175573A1 (en) 2015-06-25
MX2020013099A (es) 2022-07-26
TN2015000547A1 (fr) 2017-04-06
US20190002439A1 (en) 2019-01-03
US10093655B2 (en) 2018-10-09
WO2014207601A1 (fr) 2014-12-31
US11014909B2 (en) 2021-05-25
MX394241B (es) 2025-03-21
ES2948192T3 (es) 2023-09-01
US20170057947A1 (en) 2017-03-02
BR112015030101A2 (pt) 2017-07-25
EP3421462A1 (fr) 2019-01-02
GEP20186811B (en) 2018-01-25

Similar Documents

Publication Publication Date Title
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d&#39;inhibiteurs de ttk
MA41562B1 (fr) Agonistes d&#39;apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA42239B1 (fr) Nouveaux dérivés d&#39;hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38138A1 (fr) Dérivés inédits de quinolone
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38069A1 (fr) Composés hétéroaromatiques utilisés comme ligands de la dopamine d1
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu&#39;agents inhibiteurs de la tyrosine kinase de bruton
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA54386B1 (fr) Modulateurs de trex1
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l&#39;acyle coa-diacylglycerol transferase 1 (dgat1).
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d&#39;inhibiteurs des bromodomaines